NASDAQ:HEPA Hepion Pharmaceuticals Q2 2026 Earnings Results & Report $0.09 -0.02 (-20.95%) As of 02:09 PM Eastern Hepion Pharmaceuticals beat analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.08 versus the -$200.00 consensus estimate. Research:ProfileEarnings History Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeBefore Market OpensConference Call7:00 AM ET Hepion Pharmaceuticals EPS ResultsActual EPS-$0.08Consensus EPS -$200.00Beat/MissBeat by +$199.92One Year Ago EPSN/AHepion Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsHepion Pharmaceuticals' Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Hepion Pharmaceuticals Q2 2026 Earnings FAQ Did Hepion Pharmaceuticals beat earnings estimates for Q2 2026? Hepion Pharmaceuticals (NASDAQ:HEPA) reported earnings of -$0.08 per share for Q2 2026, beating the consensus estimate of -$200.00. The report was announced on Thursday, August 13, 2026. When is Hepion Pharmaceuticals' next earnings date? Hepion Pharmaceuticals' next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Hepion Pharmaceuticals on the company's earnings history page. Hepion Pharmaceuticals Earnings HeadlinesHepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac ArrestOctober 26, 2026 | usatoday.comHepion Pharmaceuticals Expands Authorized Share Capital for GrowthOctober 2, 2026 | tipranks.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 16 at 1:00 AM | Behind the Markets (Ad)Hepion Pharmaceuticals Announces New Private Placement FinancingAugust 4, 2026 | tipranks.comHepion Shareholders Expand Equity Plan at 2026 MeetingJune 17, 2026 | tipranks.comHepion Pharmaceuticals Announces Private Placement Financing AgreementApril 22, 2026 | tipranks.comSee More Hepion Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hepion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hepion Pharmaceuticals and other key companies, straight to your email. Email Address About Hepion PharmaceuticalsHepion Pharmaceuticals (NASDAQ:HEPA) (NASDAQ: HEPA) is a clinical-stage biopharmaceutical company focused on developing therapies for chronic liver diseases. The company’s research has centered on conditions including metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), chronic hepatitis B, and other diseases involving liver fibrosis and inflammation. Hepion’s lead investigational product, rencofilstat (formerly known as CRV431), is an oral cyclophilin inhibitor designed to address biological pathways associated with liver disease progression. The compound has been evaluated for potential applications in MASH and chronic hepatitis B, although it remains an investigational therapy and is not approved for commercial use. The company was formerly known as ContraVir Pharmaceuticals and adopted the Hepion Pharmaceuticals name in 2019. Its operations have primarily focused on research and clinical development rather than the sale of marketed products, with development activities conducted through clinical and research programs intended to support future regulatory approval.View Hepion Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.